Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among Read More
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting
Poster presentation to highlight new data on MammaPrint® and Read More
MammaPrint® Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, Read More
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024 GalleryAgendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrint® as the only commercially Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024 GalleryAgendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical Read More
Agendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics GalleryAgendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
Agendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 Read More
